This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Zofenopril
Accession Number
DB13166
Type
Small Molecule
Groups
Experimental
Description

Zofenopril is a medication that protects the heart and helps reduce high blood pressure. It is an angiotensin-converting enzyme (ACE) inhibitor.

Structure
Thumb
Synonyms
  • Zofenil
  • Zofénopril
  • Zofenopril
  • Zofenoprilum
Product Ingredients
IngredientUNIICASInChI Key
Zofenopril calcium88ZQ329PU281938-43-4NSYUKKYYVFVMST-LETVYOFWSA-L
Categories
UNII
290ZY759PI
CAS number
81872-10-8
Weight
Average: 429.55
Monoisotopic: 429.106850573
Chemical Formula
C22H23NO4S2
InChI Key
IAIDUHCBNLFXEF-MNEFBYGVSA-N
InChI
InChI=1S/C22H23NO4S2/c1-15(14-28-22(27)16-8-4-2-5-9-16)20(24)23-13-18(12-19(23)21(25)26)29-17-10-6-3-7-11-17/h2-11,15,18-19H,12-14H2,1H3,(H,25,26)/t15-,18+,19+/m1/s1
IUPAC Name
(2S,4S)-1-[(2S)-3-(benzoylsulfanyl)-2-methylpropanoyl]-4-(phenylsulfanyl)pyrrolidine-2-carboxylic acid
SMILES
[H][[email protected]@](C)(CSC(=O)C1=CC=CC=C1)C(=O)N1C[[email protected]]([H])(C[[email protected]@]1([H])C(O)=O)SC1=CC=CC=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Zofenopril.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Zofenopril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Zofenopril.Approved, Investigational
AcebutololAcebutolol may increase the hypotensive activities of Zofenopril.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Zofenopril.Approved, Investigational
AcemetacinThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Zofenopril.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Zofenopril.Approved, Withdrawn
AlfuzosinAlfuzosin may increase the hypotensive activities of Zofenopril.Approved, Investigational
AliskirenAliskiren may increase the hypotensive, nephrotoxic, and hyperkalemic activities of Zofenopril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Zofenopril.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Zofenopril.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Zofenopril.Approved
AloxiprinThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Aloxiprin.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Zofenopril.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Zofenopril.Approved, Withdrawn
AmbrisentanZofenopril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Zofenopril.Experimental, Investigational
AmifostineZofenopril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hyperkalemic activities of Zofenopril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Zofenopril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Zofenopril.Approved
Aminosalicylic AcidThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Aminosalicylic Acid.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Zofenopril.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Zofenopril.Approved
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Zofenopril.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Zofenopril.Approved, Illicit, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Zofenopril.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Zofenopril.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Zofenopril.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Zofenopril.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Zofenopril.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Zofenopril.Approved, Investigational, Withdrawn
AtenololAtenolol may increase the hypotensive activities of Zofenopril.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Zofenopril.Approved
AvanafilAvanafil may increase the antihypertensive activities of Zofenopril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Zofenopril.Withdrawn
AzathioprineThe risk or severity of anemia and severe leukopenia can be increased when Zofenopril is combined with Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Zofenopril.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Zofenopril.Approved, Investigational
BalsalazideThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Balsalazide.Approved, Investigational
BarnidipineZofenopril may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Zofenopril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Zofenopril.Experimental
BendroflumethiazideThe risk or severity of hypotension can be increased when Bendroflumethiazide is combined with Zofenopril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Zofenopril.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Zofenopril.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Zofenopril.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Zofenopril.Approved
BepridilBepridil may increase the hypotensive activities of Zofenopril.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Zofenopril.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Zofenopril.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Zofenopril.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Zofenopril.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Zofenopril.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Zofenopril.Approved
BoceprevirThe serum concentration of Zofenopril can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BosentanBosentan may increase the hypotensive activities of Zofenopril.Approved, Investigational
BQ-123BQ-123 may increase the hypotensive activities of Zofenopril.Investigational
BretyliumBretylium may increase the hypotensive activities of Zofenopril.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Zofenopril.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Zofenopril.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Zofenopril.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Zofenopril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Zofenopril.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Zofenopril.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Zofenopril.Experimental
BumetanideBumetanide may increase the hypotensive activities of Zofenopril.Approved
BupranololBupranolol may increase the hypotensive activities of Zofenopril.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Zofenopril.Approved
CadralazineCadralazine may increase the hypotensive activities of Zofenopril.Experimental
CafedrineCafedrine may increase the hypotensive activities of Zofenopril.Investigational
CanagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Zofenopril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Zofenopril.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Zofenopril.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Zofenopril.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Zofenopril.Approved
CarbamazepineThe metabolism of Zofenopril can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Zofenopril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Zofenopril.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Zofenopril.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Zofenopril.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Zofenopril.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Zofenopril.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Zofenopril.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Zofenopril.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of hypotension can be increased when Chlorothiazide is combined with Zofenopril.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Zofenopril.Investigational, Withdrawn
ChlorthalidoneThe risk or severity of hypotension can be increased when Chlorthalidone is combined with Zofenopril.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Zofenopril.Approved
CicletanineCicletanine may increase the hypotensive activities of Zofenopril.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Zofenopril.Approved
CiprofloxacinThe risk or severity of ventricular arrhythmias can be increased when Zofenopril is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Zofenopril.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Zofenopril.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Zofenopril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Zofenopril.Approved
CloranololZofenopril may increase the hypotensive activities of Cloranolol.Experimental
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Zofenopril.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Zofenopril.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Zofenopril.Approved, Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Zofenopril.Approved
CyclopenthiazideThe risk or severity of hypotension can be increased when Cyclopenthiazide is combined with Zofenopril.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Zofenopril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Zofenopril.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Zofenopril.Approved
DapagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Zofenopril.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Zofenopril.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Zofenopril.Approved, Investigational
DelaprilZofenopril may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Zofenopril.Approved
DersalazineThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Dersalazine.Investigational
DeserpidineZofenopril may increase the hypotensive activities of Deserpidine.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Zofenopril.Approved, Investigational
DiazoxideDiazoxide may increase the hypotensive activities of Zofenopril.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Zofenopril.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Zofenopril.Approved, Vet Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Zofenopril.Approved, Investigational
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of Zofenopril.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Zofenopril.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Zofenopril.Experimental
DiflunisalThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Diflunisal.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Zofenopril.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Zofenopril.Approved, Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Zofenopril.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Zofenopril.Approved, Investigational
DorzolamideDorzolamide may increase the hypotensive activities of Zofenopril.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Zofenopril.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Zofenopril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Zofenopril.Approved, Investigational
DrospirenoneZofenopril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Zofenopril.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Zofenopril.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Zofenopril.Approved
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Zofenopril.Investigational
EfonidipineEfonidipine may increase the hypotensive activities of Zofenopril.Approved, Investigational
EmpagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Empagliflozin is combined with Zofenopril.Approved
EnalaprilEnalapril may increase the hypotensive activities of Zofenopril.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of Zofenopril.Approved
EndralazineEndralazine may increase the hypotensive activities of Zofenopril.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Zofenopril.Approved, Investigational
EpanololZofenopril may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Zofenopril.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Zofenopril.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Zofenopril.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Zofenopril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Zofenopril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Zofenopril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Zofenopril.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Zofenopril.Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Zofenopril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Zofenopril.Approved, Investigational
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Zofenopril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Zofenopril.Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Zofenopril.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Zofenopril.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Zofenopril.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Zofenopril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Zofenopril.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Zofenopril.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Zofenopril.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Zofenopril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Zofenopril.Approved, Investigational
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Zofenopril.Approved
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Zofenopril.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Zofenopril.Experimental
FelodipineFelodipine may increase the hypotensive activities of Zofenopril.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Zofenopril.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Zofenopril.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Zofenopril.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Zofenopril.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Zofenopril.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Zofenopril.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Zofenopril.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Zofenopril.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Zofenopril.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Zofenopril.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Zofenopril.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Zofenopril.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Zofenopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Zofenopril.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Zofenopril.Approved, Vet Approved
GarlicThe serum concentration of Zofenopril can be decreased when it is combined with Garlic.Approved
GuacetisalThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Zofenopril.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Zofenopril.Approved
GuanazodineZofenopril may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Zofenopril.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Zofenopril.Approved, Investigational
GuanoclorZofenopril may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzZofenopril may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanZofenopril may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Zofenopril.Experimental
Hemoglobin crosfumarilThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
HeparinThe risk or severity of hyperkalemia can be increased when Zofenopril is combined with Heparin.Approved, Investigational
HexamethoniumHexamethonium may increase the hypotensive activities of Zofenopril.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Zofenopril.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Zofenopril.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Zofenopril.Experimental
HydralazineHydralazine may increase the hypotensive activities of Zofenopril.Approved
HydrochlorothiazideThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Zofenopril.Approved, Vet Approved
HydroflumethiazideThe risk or severity of hypotension can be increased when Hydroflumethiazide is combined with Zofenopril.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Zofenopril.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Zofenopril.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Zofenopril.Approved, Investigational
IloprostIloprost may increase the hypotensive activities of Zofenopril.Approved, Investigational
ImidaprilImidapril may increase the hypotensive activities of Zofenopril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Zofenopril.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Zofenopril.Approved
IndapamideThe risk or severity of hypotension can be increased when Indapamide is combined with Zofenopril.Approved
IndenololIndenolol may increase the hypotensive activities of Zofenopril.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Zofenopril.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Zofenopril.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Zofenopril.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Zofenopril.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Zofenopril.Experimental
IproclozideIproclozide may increase the hypotensive activities of Zofenopril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Zofenopril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Zofenopril.Approved, Investigational
IronIron can cause a decrease in the absorption of Zofenopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Zofenopril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Zofenopril.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Zofenopril.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Zofenopril.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Zofenopril.Experimental
KetanserinKetanserin may increase the hypotensive activities of Zofenopril.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Zofenopril.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Zofenopril.Approved
LabetalolLabetalol may increase the hypotensive activities of Zofenopril.Approved
LacidipineLacidipine may increase the hypotensive activities of Zofenopril.Approved, Investigational
Lanthanum carbonateThe serum concentration of Zofenopril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Zofenopril.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Zofenopril.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Zofenopril.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Zofenopril.Approved
LinsidomineZofenopril may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Zofenopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Zofenopril.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Zofenopril.Approved
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Zofenopril.Experimental
LofexidineLofexidine may increase the hypotensive activities of Zofenopril.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Zofenopril.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Zofenopril.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Zofenopril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Zofenopril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Zofenopril.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Zofenopril.Approved, Investigational
MacitentanZofenopril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Zofenopril.Approved
ManidipineManidipine may increase the hypotensive activities of Zofenopril.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Zofenopril.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Zofenopril.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Zofenopril.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Zofenopril.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Zofenopril.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Zofenopril.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Mesalazine.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Zofenopril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Zofenopril.Approved, Investigational, Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Zofenopril.Experimental
MethoserpidineZofenopril may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of hypotension can be increased when Methyclothiazide is combined with Zofenopril.Approved
Methyl salicylateThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MethyldopaMethyldopa may increase the hypotensive activities of Zofenopril.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Zofenopril.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Zofenopril.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Zofenopril.Approved, Investigational
MetipranololMetipranolol may increase the hypotensive activities of Zofenopril.Approved
MetolazoneThe risk or severity of hypotension can be increased when Metolazone is combined with Zofenopril.Approved
MetoprololMetoprolol may increase the hypotensive activities of Zofenopril.Approved, Investigational
MetyrosineZofenopril may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Zofenopril.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Zofenopril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Zofenopril.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Zofenopril.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Zofenopril.Investigational
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Zofenopril.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Zofenopril.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Zofenopril.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Zofenopril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Zofenopril.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Zofenopril.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Zofenopril.Approved, Investigational
MuzolimineZofenopril may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Zofenopril.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zofenopril.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Zofenopril.Approved
NadololNadolol may increase the hypotensive activities of Zofenopril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Zofenopril.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Zofenopril.Approved
NaftopidilNaftopidil may increase the hypotensive activities of Zofenopril.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Zofenopril.Approved, Vet Approved
NebivololNebivolol may increase the hypotensive activities of Zofenopril.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Zofenopril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Zofenopril.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Zofenopril.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Zofenopril.Approved, Investigational
NicorandilNicorandil may increase the vasodilatory activities of Zofenopril.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Zofenopril.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Zofenopril.Approved
NiguldipineNiguldipine may increase the hypotensive activities of Zofenopril.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Zofenopril.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Zofenopril.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Zofenopril.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Zofenopril.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Zofenopril.Approved, Investigational
NitroaspirinThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Nitroaspirin.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Zofenopril.Approved, Investigational
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Zofenopril.Approved
ObinutuzumabZofenopril may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Zofenopril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Zofenopril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zofenopril.Approved
OlsalazineThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Zofenopril.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Zofenopril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Zofenopril.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Zofenopril.Approved
OxprenololOxprenolol may increase the hypotensive activities of Zofenopril.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Zofenopril.Approved, Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Zofenopril.Approved
PargylinePargyline may increase the hypotensive activities of Zofenopril.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Zofenopril.Approved, Investigational
PenbutololPenbutolol may increase the hypotensive activities of Zofenopril.Approved, Investigational
PentoliniumPentolinium may increase the hypotensive activities of Zofenopril.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Zofenopril.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Zofenopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Zofenopril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Zofenopril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Zofenopril.Withdrawn
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Zofenopril.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Zofenopril.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Zofenopril.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Zofenopril.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Zofenopril.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Zofenopril.Approved
PindololPindolol may increase the hypotensive activities of Zofenopril.Approved, Investigational
PiretanidePiretanide may increase the hypotensive activities of Zofenopril.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Zofenopril.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Zofenopril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Zofenopril.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Zofenopril.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Zofenopril.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Zofenopril.Experimental
PolythiazideThe risk or severity of hypotension can be increased when Polythiazide is combined with Zofenopril.Approved
PotassiumPotassium may increase the hyperkalemic activities of Zofenopril.Approved, Investigational
Potassium bicarbonatePotassium bicarbonate may increase the hyperkalemic activities of Zofenopril.Approved
Potassium ChloridePotassium Chloride may increase the hyperkalemic activities of Zofenopril.Approved, Withdrawn
Potassium CitratePotassium Citrate may increase the hyperkalemic activities of Zofenopril.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Zofenopril.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Zofenopril.Approved
PregabalinThe risk or severity of angioedema can be increased when Zofenopril is combined with Pregabalin.Approved, Illicit, Investigational
ProcarbazineProcarbazine may increase the hypotensive activities of Zofenopril.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Zofenopril.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Zofenopril.Approved, Investigational
PropranololPropranolol may increase the hypotensive activities of Zofenopril.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Zofenopril.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Zofenopril.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Zofenopril.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Zofenopril.Investigational
QuinaprilQuinapril may increase the hypotensive activities of Zofenopril.Approved, Investigational
QuinethazoneThe risk or severity of hypotension can be increased when Quinethazone is combined with Zofenopril.Approved
QuinineQuinine may increase the hypotensive activities of Zofenopril.Approved
RamiprilRamipril may increase the hypotensive activities of Zofenopril.Approved
RasagilineRasagiline may increase the hypotensive activities of Zofenopril.Approved
RemikirenRemikiren may increase the hypotensive activities of Zofenopril.Approved
RescinnamineZofenopril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Zofenopril.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Zofenopril.Approved, Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Zofenopril.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Zofenopril.Approved
RituximabZofenopril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Zofenopril.Approved, Investigational, Withdrawn
SacubitrilThe risk or severity of angioedema can be increased when Zofenopril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Zofenopril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Zofenopril.Approved
Salicylic acidThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Zofenopril.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Zofenopril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Zofenopril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Zofenopril.Approved
SelegilineSelegiline may increase the hypotensive activities of Zofenopril.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the hypotensive activities of Zofenopril.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Zofenopril.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Zofenopril.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Zofenopril.Investigational
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Zofenopril.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Zofenopril.Approved
SirolimusThe risk or severity of angioedema can be increased when Sirolimus is combined with Zofenopril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Zofenopril.Approved, Investigational
SitaxentanZofenopril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Zofenopril is combined with Sodium aurothiomalate.Approved, Investigational
Sodium phosphateZofenopril may increase the nephrotoxic activities of Sodium phosphate.Approved
SpiraprilSpirapril may increase the hypotensive activities of Zofenopril.Approved
SpironolactoneSpironolactone may increase the hyperkalemic activities of Zofenopril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Zofenopril.Investigational
St. John's WortThe metabolism of Zofenopril can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Zofenopril.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Zofenopril.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Zofenopril.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Zofenopril.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Zofenopril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Zofenopril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Zofenopril.Approved, Investigational
TalinololTalinolol may increase the hypotensive activities of Zofenopril.Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Zofenopril.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Zofenopril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Zofenopril.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Zofenopril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Zofenopril is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Zofenopril.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Zofenopril.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Zofenopril.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Zofenopril.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Zofenopril.Approved, Investigational
TetrahydropalmatineTetrahydropalmatine may increase the hypotensive activities of Zofenopril.Investigational
TheodrenalineTheodrenaline may increase the hypotensive activities of Zofenopril.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Zofenopril.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Zofenopril.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Zofenopril.Approved
TiboloneTibolone may increase the hypotensive activities of Zofenopril.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of Zofenopril.Withdrawn
TimololTimolol may increase the hypotensive activities of Zofenopril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Zofenopril.Investigational
TipranavirThe serum concentration of Zofenopril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of hypotension can be increased when Tizanidine is combined with Zofenopril.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Zofenopril.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Zofenopril.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Zofenopril.Approved
TolonidineZofenopril may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Zofenopril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Zofenopril.Approved
TorasemideTorasemide may increase the hypotensive activities of Zofenopril.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Zofenopril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Zofenopril.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Zofenopril.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Zofenopril.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Zofenopril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Zofenopril.Approved, Investigational
TriamtereneTriamterene may increase the hyperkalemic activities of Zofenopril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Zofenopril.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Zofenopril.Experimental
TrichlormethiazideThe risk or severity of hypotension can be increased when Trichlormethiazide is combined with Zofenopril.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Zofenopril.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Zofenopril.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Zofenopril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Zofenopril.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Zofenopril.Investigational
Trolamine salicylateThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Trolamine salicylate.Approved
UdenafilUdenafil may increase the antihypertensive activities of Zofenopril.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Zofenopril.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Zofenopril.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Zofenopril.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Zofenopril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Zofenopril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Zofenopril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Zofenopril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Zofenopril.Approved, Investigational
VincamineZofenopril may increase the hypotensive activities of Vincamine.Experimental
VinpocetineVinpocetine may increase the hypotensive activities of Zofenopril.Investigational
XipamideZofenopril may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Zofenopril.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Zofenopril.Approved, Investigational, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Zofenopril.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Zofenopril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Zofenopril.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Zofenopril.Withdrawn
Food Interactions
Not Available

References

General References
  1. Nilsson P: Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press Suppl. 2007 Oct;2:25-30. [PubMed:18046976]
  2. Mallion JM: An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press Suppl. 2007 Oct;2:13-8. [PubMed:18046974]
External Links
KEGG Drug
D08688
PubChem Compound
92400
PubChem Substance
347829273
ChemSpider
83422
BindingDB
50084629
ChEBI
78539
ChEMBL
CHEMBL331378
Wikipedia
Zofenopril
ATC Codes
C09BA15 — Zofenopril and diureticsC09AA15 — Zofenopril

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00311 mg/mLALOGPS
logP3.64ALOGPS
logP4.31ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)3.5ChemAxon
pKa (Strongest Basic)-1.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area74.68 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity116.82 m3·mol-1ChemAxon
Polarizability44.25 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as proline and derivatives. These are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Proline and derivatives
Alternative Parents
N-acyl-L-alpha-amino acids / Thiobenzoic acids and derivatives / Benzoic acids and derivatives / Thiophenol ethers / Pyrrolidine carboxylic acids / Benzoyl derivatives / N-acylpyrrolidines / Alkylarylthioethers / Tertiary carboxylic acid amides / Thioesters
show 10 more
Substituents
N-acyl-alpha amino acid or derivatives / N-acyl-l-alpha-amino acid / N-acyl-alpha-amino acid / Proline or derivatives / Thiobenzoic acid or derivatives / Benzoic acid or derivatives / Pyrrolidine carboxylic acid or derivatives / Thiophenol ether / Pyrrolidine carboxylic acid / N-acylpyrrolidine
show 27 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
thioester, aryl sulfide, N-acyl-L-amino acid, L-proline derivative (CHEBI:78539)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Ambrosioni E: Defining the role of zofenopril in the management of hypertension and ischemic heart disorders. Am J Cardiovasc Drugs. 2007;7(1):17-24. [PubMed:17355163]

Drug created on February 11, 2017 08:59 / Updated on December 01, 2017 17:32